G-quadruplex Stabilization Fuels the ALT Pathway in ALT-positive Osteosarcoma Cells.
ALT
G-quadruplex
RHPS4
replicative stress
telomeres
Journal
Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097
Informations de publication
Date de publication:
13 03 2020
13 03 2020
Historique:
received:
31
01
2020
revised:
20
02
2020
accepted:
09
03
2020
entrez:
19
3
2020
pubmed:
19
3
2020
medline:
30
1
2021
Statut:
epublish
Résumé
Most human tumors maintain telomere lengths by telomerase, whereas a portion of them (10%-15%) uses a mechanism named alternative lengthening of telomeres (ALT). The telomeric G-quadruplex (G4) ligand RHPS4 is known for its potent antiproliferative effect, as shown in telomerase-positive cancer models. Moreover, RHPS4 is also able to reduce cell proliferation in ALT cells, although the influence of G4 stabilization on the ALT mechanism has so far been poorly investigated. Here we show that sensitivity to RHPS4 is comparable in ALT-positive (U2OS; SAOS-2) and telomerase-positive (HOS) osteosarcoma cell lines, unlinking the telomere maintenance mechanism and RHPS4 responsiveness. To investigate the impact of G4 stabilization on ALT, the cardinal ALT hallmarks were analyzed. A significant induction of telomeric doublets, telomeric clusterized DNA damage, ALT-associated Promyelocytic Leukaemia-bodies (APBs), telomere sister chromatid exchanges (T-SCE) and c-circles was found exclusively in RHPS4-treated ALT cells. We surmise that RHPS4 affects ALT mechanisms through the induction of replicative stress that in turn is converted in DNA damage at telomeres, fueling recombination. In conclusion, our work indicates that RHPS4-induced telomeric DNA damage promotes overactivation of telomeric recombination in ALT cells, opening new questions on the therapeutic employment of G4 ligands in the treatment of ALT positive tumors.
Identifiants
pubmed: 32183119
pii: genes11030304
doi: 10.3390/genes11030304
pmc: PMC7140816
pii:
doi:
Substances chimiques
Telomerase
EC 2.7.7.49
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Références
Cancer Res. 2018 Nov 1;78(21):6282-6296
pubmed: 30166419
Cell. 1995 Mar 24;80(6):837-45
pubmed: 7697714
Oncotarget. 2018 Aug 28;9(67):32868-32880
pubmed: 30214690
Methods. 2017 Feb 1;114:39-45
pubmed: 27530378
Oncogene. 1989 Dec;4(12):1483-8
pubmed: 2531855
Int J Mol Sci. 2018 Feb 18;19(2):
pubmed: 29463031
Genes Dev. 2005 Sep 15;19(18):2100-10
pubmed: 16166375
Mol Pharmacol. 2004 Nov;66(5):1138-46
pubmed: 15304549
FEBS J. 2018 Oct;285(20):3769-3785
pubmed: 30095224
J Clin Invest. 2013 May;123(5):2049-63
pubmed: 23563309
Carcinogenesis. 2010 Jan;31(1):9-18
pubmed: 19887512
Mutagenesis. 2001 Jan;16(1):85-9
pubmed: 11139603
Molecules. 2019 Apr 22;24(8):
pubmed: 31013622
Genes Dev. 2010 Jun 15;24(12):1253-65
pubmed: 20504901
Cold Spring Harb Symp Quant Biol. 2000;65:253-63
pubmed: 12760039
Science. 2011 Mar 4;331(6021):1199-203
pubmed: 21252315
Cancer Res. 1997 Aug 15;57(16):3562-8
pubmed: 9270029
FEBS J. 2018 Apr;285(7):1226-1236
pubmed: 29484821
Radiat Res. 2010 Nov;174(5):539-49
pubmed: 20726710
EMBO Rep. 2016 Dec;17(12):1731-1737
pubmed: 27760777
DNA Repair (Amst). 2015 Jan;25:104-15
pubmed: 25467559
Cancer Res. 2003 Jun 15;63(12):3247-56
pubmed: 12810655
EMBO Rep. 2017 Jun;18(6):914-928
pubmed: 28487353
Nucleic Acids Res. 2014 Apr;42(7):4391-405
pubmed: 24500201
Methods. 2017 Feb 1;114:74-84
pubmed: 27595911
Nat Commun. 2015 Jul 06;6:7538
pubmed: 26143912
Bioessays. 2007 Feb;29(2):155-65
pubmed: 17226803
Nat Commun. 2019 Feb 26;10(1):943
pubmed: 30808951
Hum Mol Genet. 2011 Jul 1;20(13):2603-10
pubmed: 21505078
PLoS One. 2009 Sep 09;4(9):e6919
pubmed: 19742304
Sci Rep. 2019 Mar 14;9(1):4544
pubmed: 30872698
Cell. 2009 Jul 10;138(1):90-103
pubmed: 19596237
J Cell Biol. 2004 Jul 19;166(2):161-5
pubmed: 15249582
Nat Rev Genet. 2010 May;11(5):319-30
pubmed: 20351727
J Virol. 2017 Jun 26;91(14):
pubmed: 28468887
Cancer Cell. 2015 Sep 14;28(3):357-69
pubmed: 26373281
Nat Commun. 2016 Aug 17;7:12534
pubmed: 27531349
Mol Carcinog. 2019 Sep;58(9):1581-1588
pubmed: 31062416
Oncogene. 2002 Jan 21;21(4):532-40
pubmed: 11850778
Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2672-7
pubmed: 11854467
Nature. 2012 Feb 22;483(7391):589-93
pubmed: 22367537
Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2393-7
pubmed: 7892278
Oncogene. 2005 Apr 21;24(18):2917-28
pubmed: 15735722
Genome Res. 2010 Mar;20(3):351-60
pubmed: 20110566
Nature. 2016 Nov 3;539(7627):54-58
pubmed: 27760120
Mutat Res. 2017 Jul;773:204-219
pubmed: 28927529
Nat Commun. 2014 Oct 21;5:5220
pubmed: 25330849
Nucleic Acids Res. 2009 Sep;37(16):5353-64
pubmed: 19596811
Curr Top Med Chem. 2015;15(19):1940-6
pubmed: 25980416
Science. 2011 Jul 22;333(6041):425
pubmed: 21719641
Nucleus. 2012 May-Jun;3(3):263-75
pubmed: 22572954
Science. 2007 Nov 2;318(5851):798-801
pubmed: 17916692
J Exp Clin Cancer Res. 2019 Jul 16;38(1):311
pubmed: 31311580
Mol Cell Biol. 2017 Sep 26;37(20):
pubmed: 28760773
Nucleic Acids Res. 2008 Mar;36(4):1200-8
pubmed: 18158301
J Clin Invest. 2007 Nov;117(11):3236-47
pubmed: 17932567
Cell. 2010 Mar 5;140(5):678-91
pubmed: 20211137
Mol Pharmacol. 2001 Nov;60(5):981-8
pubmed: 11641426
Science. 1990 Dec 14;250(4987):1576-80
pubmed: 2274789
Cell. 2014 Sep 25;159(1):108-121
pubmed: 25259924
PLoS One. 2012;7(8):e41401
pubmed: 22870217
Front Biosci (Landmark Ed). 2013 Jan 01;18:1-20
pubmed: 23276906